Callisto Pharmaceuticals Inc - Current report filing (8-K)
13 December 2007 - 7:44AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 10,
2007
Callisto
Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-32325
|
|
13-3894575
|
(State or other jurisdiction
|
|
(Commission
|
|
IRS Employer
|
of incorporation or organization)
|
|
File Number)
|
|
Identification No.)
|
420 Lexington Avenue, Suite 1609
|
New York, New York 10170
|
(Address of principal executive offices)
|
Registrants telephone number, including area code:
(212) 297-0010
(Former name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
o
|
|
Written communication
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
o
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 10, 2007, Callisto Pharmaceuticals, Inc. (the Company) entered into an Amended and Restated Employment Agreement (the Amendment Agreement) with Bernard Denoyer, Senior Vice President, Finance of the Company (the Executive). The Amendment Agreement extends the term of the employment agreement between the Company and the Executive dated as of January 15, 2004, as amended October 19, 2005, to December 1, 2008.
Among other things, the Amendment Agreement increases the Executives salary from $120,000 to $162,000 per year (the Base Salary) and he shall be eligible to earn a cash bonus of up to 15% of the Base Salary for each twelve month period during the term of the Amendment Agreement at the discretion of the Compensation Committee of the Companys Board of Directors.
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Dated: December 12, 2007
|
CALLISTO
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/
Gary S. Jacob
|
|
|
|
Gary
S. Jacob, Ph.D.
|
|
|
Chief
Executive Officer
|
|
|
|
|
|
2
Callisto (AMEX:KAL)
Historical Stock Chart
From Nov 2024 to Dec 2024
Callisto (AMEX:KAL)
Historical Stock Chart
From Dec 2023 to Dec 2024
Real-Time news about Callisto Pharmaceuticals, (American Stock Exchange): 0 recent articles
More Callisto Pharmaceuticals Inc News Articles